Evidence map›Paper›PMID 38215766›Full record

SynthesisThe Lancet. Microbe2024

Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis.

Camus Nimmo, Neda Bionghi, Matthew J Cummings, Rubeshan Perumal, Madeleine Hopson, Shamim Al Jubaer, Kogieleum Naidoo, Allison Wolf, Barun Mathema, Michelle H Larsen and 1 more

Open access · goldAbstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in The Lancet. Microbe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. A Case of Transmission of Bedaquiline- and Linezolid-Resistant Tuberculosis.International journal of molecular sciences · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Newer regimen for drug resistant-tuberculosis: A ray of hope or threatening shadows.Lung India : official organ of Indian Chest Society · 2025
    Article
  10. Article
  11. Frameshift mutations in theAntimicrobial agents and chemotherapy · 2024
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Camus NimmoFrancis Crick Institute, London, UK. Electronic address: camus.nimmo@crick.ac.uk.
Neda BionghiDepartment of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.
Matthew J CummingsDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Rubeshan PerumalCAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa; Division of Pulmonology and Critical Care, Department of Medicine, Inkosi Albert Luthuli Central Hospital, University of KwaZulu-Natal, Durban, South Africa.
Madeleine HopsonDepartment of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.
Shamim Al JubaerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Kogieleum NaidooCAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Allison WolfDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Barun MathemaDepartment of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Michelle H LarsenDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Max O'DonnellDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA; CAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa; Division of Pulmonology and Critical Care, Department of Medicine, Inkosi Albert Luthuli Central Hospital, University of KwaZulu-Natal, Durban, South Africa.
Columbia University Irving Medical Center · USSouth African Medical Research Council · ZAAlbert Einstein College of Medicine · USNewYork–Presbyterian Hospital · USThe Francis Crick Institute · GB

Funding

Novel Reporter Phages to Detect Complex TB Drug Resistance and PersistenceR01AI114900 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Michelle H Larsen, Max O'Donnell · 2015 to 2026
$7.2M
Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phageR01AI176407 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2023 to 2026
$3.0M
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaR01AI167795 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2022 to 2026
$2.9M
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South AfricaR01AI124413 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX, PADAYATCHI, NESRI · 2016 to 2020
$2.7M
Subtyping sepsis in Uganda using clinical, pathogen, and host response profilingK23AI163364 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CUMMINGS, MATTHEW JOHN · 2022 to 2025
$733k
Cancer Research UKMedical Research Council MC_PC_16022NIAID NIH HHS K23 AI163364NIAID NIH HHS R01 AI114900NIAID NIH HHS R01 AI124413NIAID NIH HHS R01 AI167795NIAID NIH HHS R01 AI176407Wellcome Trust CC2169
6 · The paper itself

Abstract

backgroundClinical bedaquiline resistance predominantly involves mutations in mmpR5 (Rv0678). However, mmpR5 resistance-associated variants (RAVs) have a variable relationship with phenotypic Mycobacterium tuberculosis resistance. We did a systematic review to assess the maximal sensitivity of sequencing bedaquiline resistance-associated genes and evaluate the association between RAVs and phenotypic resistance, using traditional and machine-based learning techniques.

methodsWe screened public databases for articles published from database inception until Oct 31, 2022. Eligible studies performed sequencing of at least mmpR5 and atpE on clinically sourced M tuberculosis isolates and measured bedaquiline minimum inhibitory concentrations (MICs). A bias risk scoring tool was used to identify bias. Individual genetic mutations and corresponding MICs were aggregated, and odds ratios calculated to determine association of mutations with resistance. Machine-based learning methods were used to define test characteristics of parsimonious sets of diagnostic RAVs, and mmpR5 mutations were mapped to the protein structure to highlight mechanisms of resistance. This study was registered in the PROSPERO database (CRD42022346547).

findings18 eligible studies were identified, comprising 975 M tuberculosis isolates containing at least one potential RAV (mutation in mmpR5, atpE, atpB, or pepQ), with 201 (20·6%) showing phenotypic bedaquiline resistance. 84 (29·5%) of 285 resistant isolates had no candidate gene mutation. Sensitivity and positive predictive value of taking an any mutation approach was 69% and 14%, respectively. 13 mutations, all in mmpR5, had a significant association with a resistant MIC (adjusted p<0·05). Gradient-boosted machine classifier models for predicting intermediate or resistant and resistant phenotypes both had receiver operator characteristic c statistic of 0·73 (95% CI 0·70-0·76). Frameshift mutations clustered in the α1 helix DNA-binding domain, and substitutions in the α2 and α3 helix hinge region and in the α4 helix-binding domain.

interpretationSequencing candidate genes is insufficiently sensitive to diagnose clinical bedaquiline resistance, but where identified, some mutations should be assumed to be associated with resistance. Genomic tools are most likely to be effective in combination with rapid phenotypic diagnostics. This study was limited by selective sampling in contributing studies and only considering single genetic loci as causative of resistance.

fundingFrancis Crick Institute and National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Indexed as

Antitubercular AgentsDiarylquinolinesMicrobial Sensitivity TestsMutationMycobacterium tuberculosisTuberculosis, Multidrug-ResistantBacterial ProteinsDrug Resistance, BacterialGenomicsHumansAntitubercular AgentsBacterial ProteinsbedaquilineDiarylquinolines

Identifiers

PMID38215766
PMCPMC11072239
OpenAlexW4390725532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.